NEW
Dragon Pharma, Europe
GW501516
Oral · 20 mg/tab · 100 tabs
$140.00
Compound ID
Cardarine
Dosage
10–20 mg/day
Concentration
20 mg/tablet
Form
100 Tablets × 20 mg
Half-life
Approximately 16–24 hours
Properties
Shipping
Not available in this combination
Product overview
Dragon Pharma GW501516 20mg — PPARδ Agonist for Elite Endurance, Fat Oxidation & Metabolic Optimization
Dragon Pharma GW501516 20mg, recognized throughout the performance community as Cardarine, represents a paradigm shift in non-hormonal ergogenic supplementation. Rather than interacting with androgen receptors or suppressing endocrine function, this compound operates as a potent PPARδ (peroxisome proliferator-activated receptor delta) agonist, fundamentally reprogramming cellular energy metabolism to favor lipid oxidation over glycogenolysis. The result is a dramatic expansion of aerobic and anaerobic capacity, accelerated adipose tissue mobilization, and favorable lipid profile modulation—all without the androgenic side effects, hepatic stress, or hormonal suppression characteristic of traditional anabolic agents. Dragon Pharma's precisely manufactured 20mg tablets, verified by independent analytical testing, provide athletes with a reliable, research-backed tool for breaking through endurance plateaus and achieving peak metabolic conditioning.
What is Dragon Pharma GW501516?
GW501516 is a synthetic ligand developed to activate the PPARδ nuclear receptor, a transcription factor that governs the expression of genes involved in fatty acid oxidation, mitochondrial biogenesis, and energy homeostasis. Upon binding, Cardarine upregulates key enzymes within the β-oxidation pathway, enabling skeletal muscle to derive a substantially greater proportion of ATP from stored triglycerides rather than muscle glycogen or blood glucose. This metabolic shift conserves intramuscular carbohydrate reserves, delays the onset of fatigue, and enhances substrate utilization efficiency across both low-intensity steady-state and high-intensity interval training. Unlike SARMs or anabolic steroids, GW501516 does not modulate the hypothalamic-pituitary-gonadal axis and exhibits no affinity for androgen receptors, rendering it completely non-suppressive and suitable for extended integration into virtually any training or supplementation protocol.
Key Benefits / Effects
- Substantial Endurance Amplification: Users consistently report the ability to add multiple repetitions per set, extend cardio session duration, and drastically reduce inter-set recovery intervals due to glycogen-sparing metabolic adaptation.
- Accelerated Lipolysis: Upregulation of fat-oxidation genes transforms the body into a more efficient lipid-burning system, particularly effective against stubborn adipose deposits resistant to conventional caloric deficit.
- Favorable Lipid Profile Modulation: Clinical and anecdotal data demonstrate significant elevation of HDL cholesterol alongside reductions in LDL cholesterol and triglycerides, supporting cardiovascular health during intensive training phases.
- Enhanced Insulin Sensitivity: Improved glucose uptake by skeletal muscle promotes stable energy levels, reduces post-prandial blood sugar spikes, and minimizes adipogenic storage of dietary carbohydrates.
- Lean Tissue Preservation: By optimizing fuel selection toward fatty acids, Cardarine prevents the catabolic breakdown of muscle protein for energy during hypocaloric cutting phases.
- Non-Hormonal Safety Profile: Absence of androgen receptor interaction eliminates testosterone suppression, estrogen conversion, and the need for post-cycle therapy or organ-support supplements.
How Dragon Pharma GW501516 Works
The compound's mechanism initiates at the nuclear receptor level, where GW501516 binds to PPARδ and forms a heterodimer with the retinoid X receptor (RXR). This complex translocates to the nucleus and attaches to peroxisome proliferator response elements (PPREs) on target genes, upregulating the expression of proteins critical to mitochondrial fatty acid oxidation, uncoupling, and energy expenditure. In practical terms, skeletal muscle increases its capacity to import, transport, and combust long-chain fatty acids within the mitochondrial matrix. Concurrently, the compound enhances the expression of genes involved in reverse cholesterol transport and HDL synthesis, contributing to its cardioprotective lipid profile effects. The net physiological outcome is a body that preferentially burns adipose tissue for fuel while sparing glycogen and muscle protein, enabling longer, more intense training sessions and superior body composition outcomes.
Usage Information
Dragon Pharma GW501516 is supplied as 20mg oral tablets with a pharmacokinetic half-life of 16–24 hours, supporting flexible once-daily dosing. Novice users should begin at 10mg daily to assess individual metabolic response and tolerance. Intermediate and advanced practitioners typically employ 15–20mg daily, which represents the sweet spot for pronounced endurance and fat-loss benefits without entering diminishing-returns territory. Dosing may occur at any consistent time of day, though many athletes prefer administration 30–60 minutes pre-workout to maximize acute performance enhancement. Standard cycle duration spans 8–12 weeks, followed by an equal-length off period to preserve receptor sensitivity and prevent adaptive downregulation. No post-cycle therapy is required, and the compound may be seamlessly integrated into cutting, recomposition, or even bulking protocols where endurance and nutrient partitioning are priorities.
Quality & Manufacturing
Dragon Pharma enforces uncompromising quality-control protocols across all manufacturing stages, with independent third-party laboratories analyzing every batch for identity, purity, and potency. Recent analytical verification confirmed an actual GW501516 content of 21.70mg per tablet—marginally exceeding the stated 20mg dose to ensure users receive the full intended pharmacological effect. This overage policy reflects Dragon Pharma's commitment to delivering value and consistency rather than cutting corners. In a market saturated with mislabeled research chemicals, counterfeit PPAR agonists, and dangerously underdosed alternatives, this level of analytical transparency provides athletes with the confidence to design protocols based on accurate, predictable dosing.
Possible Side Effects / Safety Information
- Rodent Carcinogenicity Debate: Long-term studies in rodents administered supraphysiological doses (equivalent to human doses exceeding 100mg daily for years) demonstrated increased tumor incidence across multiple organ systems. No such findings have emerged in primate or human trials at standard performance doses, and the translational relevance of rodent data to typical human usage patterns remains scientifically contested.
- Initial Adaptation Symptoms: Some users report mild headaches, transient lethargy, or slight nausea during the first 3–5 days as metabolic pathways shift toward increased fat oxidation; these effects typically resolve spontaneously.
- Receptor Desensitization: Continuous, uninterrupted use beyond 12 weeks may lead to adaptive downregulation of PPARδ response, justifying structured cycling with off periods to restore full sensitivity.
- Absence of Hepatotoxicity: Unlike C17-alpha alkylated oral steroids, GW501516 does not stress hepatic enzyme systems and requires no liver support supplementation.
- Non-Suppressive Nature: No impact on testosterone, estrogen, or luteinizing hormone levels eliminates the need for PCT and minimizes endocrine disruption risk.
Why Choose Dragon Pharma GW501516?
The research chemical marketplace is notoriously unreliable, with GW501516 frequently mislabeled, underdosed, or contaminated with unrelated stimulants or prohormones. Dragon Pharma eliminates this uncertainty through rigorous batch testing and transparent potency disclosure. The verified 21.70mg per tablet ensures that athletes programming 20mg daily protocols actually receive the full dose required for measurable metabolic enhancement. Whether the goal is marathon-grade endurance, competition-level leanness, or simply the ability to train harder without hormonal consequences, this formulation provides a clean, effective, and predictable platform that stands apart from unverified alternatives.
Product FAQ
Questions, answered
GW501516 is neither a SARM nor a steroid. It is a PPARδ agonist that modulates gene expression related to energy metabolism rather than binding to androgen receptors. This means it produces no testosterone suppression, no estrogenic side effects, no androgenic manifestations such as hair loss or acne, and no liver toxicity. It can be used by both men and women without endocrine disruption and requires no post-cycle therapy.
For aggressive fat loss, stack Cardarine with Ostarine (MK-2866) to preserve lean mass and SR9009 (Stenabolic) to further amplify metabolic rate and endurance. This triple combination creates a powerful non-hormonal cutting environment that protects muscle while maximizing caloric expenditure and lipid oxidation. Adding a moderate caloric deficit and regular cardiovascular training yields exceptional body recomposition results.
Yes. Multiple studies and extensive user reports indicate that GW501516 significantly increases HDL cholesterol while reducing LDL cholesterol and triglycerides. This favorable shift in lipid profiles supports arterial health and may offset some of the cardiovascular strain associated with intensive training or other performance compounds. However, it should not be viewed as a replacement for medical cardiovascular care.
No. Because GW501516 does not interact with androgen receptors or the hypothalamic-pituitary-gonadal axis, it produces zero testosterone suppression. Users can run full cycles without experiencing the lethargy, libido loss, or mood disturbances associated with hormonal shutdown. This makes it an ideal compound for bridging between steroid cycles or for athletes who wish to avoid endocrine manipulation entirely.
Most users report noticeable increases in cardiovascular capacity and training stamina within the first 7–10 days of administration. The full metabolic adaptation, including pronounced fat-loss acceleration and glycogen-sparing effects, typically consolidates by weeks 3–4. Consistent dosing and proper training intensity are essential to maximizing these benefits.
The cancer concern originates from rodent studies using extremely high doses over prolonged durations—exposure levels far exceeding typical human performance protocols. No human clinical trials have demonstrated carcinogenic effects at standard doses of 10–20mg daily for 8–12 weeks. The scientific consensus remains divided on translational relevance, and users should weigh this theoretical risk against the well-documented benefits, making informed decisions based on current evidence.
Absolutely. Because GW501516 is non-hormonal and does not interact with androgen receptors, it carries no risk of virilization, menstrual disruption, or voice deepening. Women can utilize the same 10–20mg dosing range as men and experience comparable endurance, fat-loss, and metabolic benefits without the androgenic complications associated with steroids or even some SARMs.
GW501516 can be taken with or without food, as its absorption is not significantly impacted by meal composition. Many users prefer dosing 30–60 minutes before training to capitalize on acute endurance enhancement during the workout. Consistent daily timing is more important than specific meal timing for maintaining steady-state metabolic effects.
While Clenbuterol stimulates thermogenesis through beta-adrenergic agonism and can produce jitteriness, anxiety, and cardiovascular strain, GW501516 enhances fat loss by improving metabolic efficiency and substrate utilization. Cardarine supports cardiovascular health through favorable lipid modulation, whereas Clenbuterol may negatively impact cardiac function. Many advanced users combine both compounds synergistically, using Cardarine to offset Clenbuterol's cardiovascular demands while amplifying overall fat-loss velocity.
No. GW501516 is not a C17-alpha alkylated compound and does not stress hepatic enzyme systems. Unlike oral steroids or certain prohormones, it requires no milk thistle, TUDCA, or NAC supplementation for liver protection. This clean organ profile is one of its most attractive features for long-term health-conscious athletes.
